kalvista - Search News

News

KalVista, FDA and EKTERLY

Reuters on MSN · 1d

US FDA approves KalVista's oral swelling disorder drug, shares rise

KalVista Pharmaceuticals said on Monday the U.S. Food and Drug Administration has approved its drug, the first on-demand oral treatment for a type of hereditary swelling disorder, sending its shares up more than 18%.

PharmExec · 20h

FDA Approves KalVista Pharmaceuticals’ Ekterly for Hereditary Angioedema

Ekterly becomes the first FDA-approved oral on-demand treatment for hereditary angioedema in patients aged 12 years and older.

Seeking Alpha · 13h

KalVista: FDA Approval Of EKTERLY As Oral On-Demand HAE Drug Is Just Beginning

FDA approval of EKTERLY makes KalVista Pharmaceuticals, Inc. the first to offer an oral on-demand HAE therapy. Click here to find out why KALV is a Strong Buy.

GlobalData on MSN1d

FDA approves KalVista’s Ekterly for hereditary angioedema

The US Food and Drug Administration (FDA) has approved KalVista Pharmaceuticals' Ekterly (sebetralstat) as the first and only ...

1d

Orsini Selected as Specialty Pharmacy Partner for KalVista's EKTERLY® (sebetralstat)

Orsini, a leader in rare disease pharmacy solutions, has been chosen by KalVista Pharmaceuticals as a specialty pharmacy ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results